Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Neuroscience Back In Vogue? Sanofi Preps For R&D Dominance

Executive Summary

Sanofi is building up a neuroscience portfolio from its legacy multiple sclerosis and rare disease foundations by pursuing early-stage research in neurodegeneration, neuro-inflammation and rare brain diseases. Neuroscience professor and former Pfizer drug development leader, Rita Balice-Gordon, will use her academic assessment lens to find the best science and utilize patient groups to bridge the gap between research and neuro disease therapeutics making it all the way to market.

You may also be interested in...



Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.

VC View: Deal-Making During A Pandemic And 2021 Expectations

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

Snapshot: August Highlights

A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel